已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Addition of Narrow-Band UVB Phototherapy to Ruxolitinib Cream in Patients With Vitiligo

白癜风 医学 皮肤病科 脱色 斯科普斯 科学网 梅德林 内科学 荟萃分析 政治学 法学
作者
Amit G. Pandya,John E. Harris,Mark Lebwohl,Iltefat Hamzavi,Kathleen Butler,Fiona I. Kuo,Shaoceng Wei,David Rosmarin
出处
期刊:Journal of Investigative Dermatology [Elsevier]
卷期号:142 (12): 3352-3355.e4 被引量:22
标识
DOI:10.1016/j.jid.2022.05.1093
摘要

Vitiligo is a chronic autoimmune disease resulting in patches of skin depigmentation ( Taïeb and Picardo, 2009 Taïeb A. Picardo M. Clinical practice. Vitiligo. N Engl J Med. 2009; 360: 160-169 Crossref PubMed Scopus (297) Google Scholar ) and reduced QOL ( Morrison et al., 2017 Morrison B. Burden-Teh E. Batchelor J.M. Mead E. Grindlay D. Ratib S. Quality of life in people with vitiligo: a systematic review and meta-analysis. Br J Dermatol. 2017; 177: e338-e339 Crossref PubMed Scopus (25) Google Scholar ). Disease pathogenesis is driven by IFN-γ signaling through Jak1 and 2 ( Rashighi and Harris, 2015 Rashighi M. Harris J.E. Interfering with the IFN-γ/CXCL10 pathway to develop new targeted treatments for vitiligo. Ann Transl Med. 2015; 3: 343 PubMed Google Scholar ). Combination phototherapy with topical corticosteroids or topical calcineurin inhibitors has been shown to significantly improve repigmentation versus monotherapy in patients with vitiligo ( Batchelor et al., 2020 Batchelor J.M. Thomas K.S. Akram P. Azad J. Bewley A. Chalmers J.R. et al. Home-based narrowband UVB, topical corticosteroid or combination for children and adults with vitiligo: HI-light vitiligo three-arm RCT. Health Technol Assess. 2020; 24: 1-128 Crossref PubMed Scopus (11) Google Scholar ; Dong et al., 2021 Dong Y. Yang Q. Guo B. Zhu J. Sun X. The effects of tacrolimus plus phototherapy in the treatment of vitiligo: a meta-analysis. Arch Dermatol Res. 2021; 313: 461-471 Crossref PubMed Scopus (5) Google Scholar ). Previous reports with Jak inhibitors have suggested additional therapeutic benefits with concomitant phototherapy ( Joshipura et al., 2018 Joshipura D. Alomran A. Zancanaro P. Rosmarin D. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: a 32-week open-label extension study with optional narrow-band ultraviolet B. J Am Acad Dermatol. 2018; 78: 1205-1207.e1 Abstract Full Text Full Text PDF PubMed Scopus (47) Google Scholar ; Liu et al., 2017 Liu L.Y. Strassner J.P. Refat M.A. Harris J.E. King B.A. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol. 2017; 77: 675-682.e1 Abstract Full Text Full Text PDF PubMed Scopus (119) Google Scholar ). In these patients, it has been proposed that Jak inhibition suppresses inflammatory signals that result in melanocyte destruction, leading to the potential recovery of melanocytes that may be enhanced during phototherapy-induced stimulation ( Liu et al., 2017 Liu L.Y. Strassner J.P. Refat M.A. Harris J.E. King B.A. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol. 2017; 77: 675-682.e1 Abstract Full Text Full Text PDF PubMed Scopus (119) Google Scholar ). Ruxolitinib is a Jak1/Jak2 inhibitor ( Quintás-Cardama et al., 2010 Quintás-Cardama A. Vaddi K. Liu P. Manshouri T. Li J. Scherle P.A. et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010; 115: 3109-3117 Crossref PubMed Scopus (622) Google Scholar ), and a topical formulation is in development for the treatment of vitiligo. In a phase 2, randomized, dose-ranging study in 157 adult patients with vitiligo (NCT03099304), ruxolitinib cream was associated with substantial repigmentation over 52 weeks and was well tolerated ( Rosmarin et al., 2020 Rosmarin D. Pandya A.G. Lebwohl M. Grimes P. Hamzavi I. Gottlieb A.B. et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet. 2020; 396: 110-120 Abstract Full Text Full Text PDF PubMed Scopus (104) Google Scholar ). In this study, we report the safety and efficacy of ruxolitinib cream with concomitant narrow-band UVB (NB-UVB) phototherapy during the open-label phase after week 52 of the phase 2 study.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
万能图书馆应助852采纳,获得10
刚刚
shella发布了新的文献求助10
1秒前
晓晓发布了新的文献求助10
1秒前
JZX应助科研通管家采纳,获得30
1秒前
SYLH应助科研通管家采纳,获得10
1秒前
2秒前
科研通AI5应助科研通管家采纳,获得10
2秒前
完美世界应助科研通管家采纳,获得10
2秒前
赘婿应助科研通管家采纳,获得10
2秒前
慕青应助科研通管家采纳,获得10
2秒前
乐乐应助科研通管家采纳,获得10
2秒前
2秒前
SYLH应助科研通管家采纳,获得10
2秒前
SYLH应助科研通管家采纳,获得10
2秒前
SYLH应助科研通管家采纳,获得10
2秒前
赘婿应助科研通管家采纳,获得10
2秒前
yanzu应助CHAIZH采纳,获得10
3秒前
LYegoist完成签到,获得积分10
4秒前
科研通AI5应助LSJ采纳,获得10
4秒前
科研通AI5应助week采纳,获得10
4秒前
无穷级数发布了新的文献求助10
6秒前
初雪平寒发布了新的文献求助10
6秒前
7秒前
小张发布了新的文献求助10
7秒前
8秒前
9秒前
haoryan发布了新的文献求助10
12秒前
俊逸安阳发布了新的文献求助10
12秒前
打打应助xiaobai采纳,获得10
12秒前
14秒前
大大小小发布了新的文献求助10
16秒前
16秒前
16秒前
yanzu应助一一采纳,获得10
16秒前
haoryan完成签到,获得积分10
18秒前
smallfish发布了新的文献求助10
19秒前
276868sxzz发布了新的文献求助10
20秒前
21秒前
欣喜眼神发布了新的文献求助10
22秒前
sevenvnennn完成签到,获得积分10
23秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Mechanistic Modeling of Gas-Liquid Two-Phase Flow in Pipes 2500
Structural Load Modelling and Combination for Performance and Safety Evaluation 1000
Conference Record, IAS Annual Meeting 1977 610
電気学会論文誌D(産業応用部門誌), 141 巻, 11 号 510
Virulence Mechanisms of Plant-Pathogenic Bacteria 500
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3561680
求助须知:如何正确求助?哪些是违规求助? 3135271
关于积分的说明 9411778
捐赠科研通 2835787
什么是DOI,文献DOI怎么找? 1558642
邀请新用户注册赠送积分活动 728413
科研通“疑难数据库(出版商)”最低求助积分说明 716806